ESMO 2017: Infusion-Related Reactions in Myeloma Patients Treated With Daratumumab
Most infusion-related reactions observed in patients who received the CD38-tageted monoclonal antibody daratumumab were generally mild, occurring during the first infusion, and were managed with pre- and postinfusion medications, according to an analysis of the phase III CASTOR and POLLUX trials in patients with multiple myeloma. Philippe Moreau, MD, of the University Hospital, Nantes, France, presented these findings at the 2017 European Society for Medical Oncology (ESMO) Congress in Madrid (Abstract 998PD).
When combined with standard-of-care regimens in the CASTOR trial (bortezomib and dexamethasone) and in the POLLUX trial (lenalidomide and dexamethasone), daratumumab reduced the risk of progression of multiple myeloma or death by more than 60%, Dr. Moreau and colleagues noted.
All patients treated with daratumumab received preinfusion medication, consisting of paracetamol and diphenhydramine or their equivalents. Post-infusion medications were given to 31 patients in the CASTOR trial (13%) and 21 patients in the POLLUX trial (7%).
In both trials, infusion-related reactions, mostly grade 1/2, were reported in about 45% to 48% of patients. More than 95% of these reactions occurred during the first infusion in both studies. No grade 4 or higher reactions were reported.
